This is the RSS news feed of one of our preset news channels on LSIS - The Life Science Infromation Service. Please visit us to find a current view of this one and many more channels via our alerting push services: http://www.lsis.com/channels/?query=96 http://www.lsis.com/goto/r96/rss 2012-02-05T11:11:01+01:00 text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=96 DARMSTADT, Germany, Feb 03, 2012 (BUSINESS WIRE) - -Deal provides Threshold with an upfront payment of EUR 19 million ($25 million), plus further potential milestones and royalties as well as an option to co-commercialize in the United States Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that a global agreement was signed with Threshold Pharmaceuticals, Inc., South San Francisco, to co-develop and commercialize TH-302, Threshold's small molecule hypoxia-targeted (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=96 Merck & Co. swung to a fourth-quarter profit from a year-earlier loss that was weighed down by an asset write-down for a drug-research setback, while sales inched up 2%. The Whitehouse Station, N.J., drug maker issued a forecast for full-year 2012 results that leaves room for earnings growth, while sales are expected to be flat or down due to the impending loss of U.S. patent protection for its top-selling drug, the asthma and allergy treatment Singulair. The expected generic competition for (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=96 CONFERENCE PROCEEDING Proceedings of the PDA/FDA Adventitious Viruses in Biologics: Detection and Mitigation Strategies Workshop in Bethesda, MD, USA; December 1-3, 2010 Guest Editors: Arifa Khan (Bethesda, MD), Patricia Hughes (Bethesda, MD) and Michael Wiebe (San Francisco, CA) In June of 2010, results of metagenomic and panmicrobial microarray analysis of a number of commercially available vaccine products were published, identifying the unexpected presence of porcine circovirus (PCV) in of (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=96 Although adaptive trials have become popular, little research has been done to investigate the effect of missing data in adaptive trials. We consider three different types of missing data mechanisms-missing completely at random (MCAR), missing at random (MAR), and missing not at random (MNAR)-and introduce the "mixture missing mechanism" (MMM) to an adaptive three-period crossover study that uses the "maximizing procedure." These results are compared to a traditional nonadaptive equal (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=96 Palladium-catalyzed cross-coupling conditions were developed that efficiently afford 2-aryl-2-nitroacetates from aryl bromides and the very acidic nitroacetates. |-| Org Lett. |-| Metz AE, Berritt S, Dreher SD, Kozlowski MC. |-| Penn Merck High Throughput Experimentation Laboratory, Department of Chemistry, University of Pennsylvania, Philadelphia, Pennsylvania 1910-6323, United States, and Merck & Co., Inc., Rahway, New Jersey 07065, United States. text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=96 : The usefulness of questionnaires to assess asthma control in clinical practice is recognized in recent international guidelines. While several questionnaires have been developed to measure asthma control in adults, there has been little study of the performance of such instruments in children. |-| Patient. |-| Diette GB, Sajjan SG, Skinner EA, Weiss TW, Wu AW, Markson LE. |-| 1 Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA 2 Johns Hopkins University School of (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=96 After more than 40 years, immunoassays are still the backbone of protein biomarker analysis in clinical diagnostics and drug development. They have come a long way since their inception, incorporating technical developments including monoclonal antibodies, novel labels and lately microfluidics. A number of microfluidic platforms have been tested, such as centrifugational compact disc assays, lab-on-a-chip, arrays and digital electrochemical assays. This review focuses on commercial (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=96 Recombinant therapeutic protein drugs have now been in clinical use for nearly three decades and have advanced considerably in complexity over this time period. Regulatory approvals of some early pioneering protein drugs did not require characterization of metabolism, but more recently regulatory expectations and guidance have appropriately evolved. Sponsors may now be expected to investigate metabolism of newer biologics as the structural complexity of proteins has increased markedly, (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=96 WHITEHOUSE STATION, N.J.-(BUSINESS WIRE)- Positive Opinion Recommends Approval of the First and Only Anti-TNF Therapy in Pediatric Patients with Severely Active Ulcerative Colitis, a Chronic, Inflammatory Bowel Disease MSD (also known as Merck in the United States and Canada) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the use of REMICADE (infliximab) in the treatment of severely (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=96 PASADENA, Calif., Jan. 25, 2012 /PRNewswire/ - Gardasil, the human papillomavirus vaccine that is now recommended for male and female adolescents and young adults, does not trigger autoimmune conditions such as lupus, rheumatoid arthritis, type 1 diabetes or multiple sclerosis after vaccination in young women, according to a new study in the Journal of Internal Medicine. Kaiser Permanente researchers used electronic health records to conduct an observational safety study of 189,629 females (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=96 (TAMPA, FLORIDA USA, 24 January 2012) The Facility of the Year Awards Judging Panel has named five Category Award Winners and selected one project for Special Recognition in the 2012 Facility of the Year Awards (FOYA) program. The winning projects for 2012 are located in Germany, India, Ireland, Italy, and the USA. The winning companies and respective award categories are: ¢ Chiesi Farmaceutici S.p.A., winner of the Facility of the Year Award for Sustainability for its Chiesi Farmaceutici (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=96 BOTHELL, WA-(Marketwire - January 23, 2012) - Marina Biotech, Inc. (NASDAQ: MRNAD), a leading oligonucleotide-based drug discovery and development company today announced that the Intellectual Property Office of New Zealand (IPONZ) has issued a Notice of Acceptance for patent application 580712. The claims broadly cover multiple sequence independent and length independent, nucleic acid constructs having one or more unlocked nucleobase analogs (UNAs). The nucleic acid constructs of the patent (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=96 Drugmaker Merck & Co. said Thursday that it has reached a deal to settle all lawsuits in Canada over its recalled painkiller Vioxx, for up to 36.9 million Canadian dollars ($36.5 million). Merck and attorneys representing hundreds of Vioxx users in Canada said the final payment will be at least $21.6 million and could go as high as $36.5 million. Merck and representatives of the plaintiffs have signed the agreement, which is awaiting approval by courts in Canada's provinces. Individual (…) text/html http://www.sciencedaily.com ScienceDaily http://www.lsis.com/channels/?query=96 ScienceDaily (Jan. 5, 2012) Working with mice, scientists at Johns Hopkins have successfully used a commonly prescribed blood pressure medicine, losartan (Cozaar), to prevent almost all of the lung damage caused from two months of exposure to cigarette smoke. The treatment specifically targeted lung tissue breakdown, airway wall thickening, inflammation and lung over-expansion. See Also: Health & Medicine Lung Disease Lung Cancer Diseases and Conditions Smoking Cystic Fibrosis Hypertension (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=96 Aim:? Anacetrapib is currently being developed for the treatment of dyslipidemia. Since warfarin, an anticoagulant with a narrow therapeutic index, is expected to be commonly prescribed in this population a drug interaction study was conducted. Methods:? In a randomized, open-label, 2-period fixed-sequence design, 12 healthy male subjects received two different treatments (Treatment A followed by Treatment B). In Treatment A, a single oral dose of 30 mg warfarin (3 x 10 mg COUMADIN(TM) ) (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=96 Summary.? In chronic hepatitis C (CHC), treatment duration may be individualized according to time to first undetectable hepatitis C virus (HCV) RNA, with patients who attain undetectable HCV RNA early in treatment being candidates for shorter regimens. The aim of this study was to determine the relapse rate in patients with CHC genotype (G) 1 infection and low baseline viral load who achieved undetectable HCV RNA by week 4 [rapid virologic response (RVR)] when treated for 24?weeks. This (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=96 OBJECTIVE: To study the characteristics of unintentional muscle activities in clinical EEG, and to develop a high-throughput method to reduce them for better revealing drug or biological effects on EEG. METHODS: Two clinical EEG datasets are involved. Pure muscle signals are extracted from EEG using Independent Component Analysis (ICA) for studying their characteristics. A high-throughput method called ICA-SR is introduced based on a new feature named Spectral Ratio (SR). RESULTS: The spectral (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=96 MONKLANDS is this week celebrating a much-needed jobs boost. The site of the former MSD/Organon research facility in Chapelhall will be transformed into a dedicated base for bioscience, pharmaceutical, and healthcare companies, creating hundreds of new jobs. And John Swinney, the cabinet secretary for finance, employment and sustainable growth will make the announcement at the Bo ness Road site today (Wednesday). The joint venture between BioCity Nottingham and Roslin BioCentre has been (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=96 Merck & Co. (MRK) will consider making acquisitions as part of its strategy to develop the next generation of hepatitis C treatments, the drug maker's research chief said Tuesday. The search for better hepatitis C drugs has produced some eye-popping deals in the drug industry recently, including Gilead Sciences Inc. (GILD) planned $11 billion purchase of Pharmasset Inc. (VRUS) and Bristol-Myers Squibb Co.'s (BMY) agreement to acquire Inhibitex Inc. (INHX) for $2.5 billion. text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=96 Cerebrospinal fluid (CSF) provides a window into central nervous system (CNS) physiology and pathophysiology in human neurodegenerative conditions such as Alzheimer's disease. Changes in CSF bioanalytes also provide a direct readout of target engagement in the CNS following pharmacological interventions in clinical trials. Given the importance of tracking CNS bioanalytes in drug discovery, we have developed a novel cisterna magna cannulated rat model for repeated CSF sampling and used it to (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=96 FOSTER CITY, CA-(Marketwire - January 09, 2012) - SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced its anticipated full-year 2011 revenues and year-end cash position, and provided its 2012 initial revenue and year-end cash guidance as follows: For 2011, the Company anticipates revenues of approximately $134 million (unaudited) including revenues of NovaMed Pharmaceuticals, Inc. (NovaMed) following the acquisition in April 2011, a 57% increase over 2010. Cash and investments are (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=96 Single-dose montelukast attenuates exercise-induced bronchoconstriction (EIB) in adults within 2 hours postdose and lasting through 24 hours. This study evaluated the onset and duration of EIB attenuation in children after a single dose of montelukast. A randomized, double-blind, placebo-controlled, two-period crossover study was performed. Patients (n = 66) aged 4-14 years, with preexercise forced expiratory volume in 1 second of (FEV(1) ?70% predicted and maximum percentage fall in (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=96 HIV-1 integrase is one of the three viral enzymes essential to HIV replication. Consequently the development of therapeutics targeting this enzyme has been a major focus of antiretroviral research over the past two decades. Several classes of integrase inhibitors have been identified; of these the diketoacids (DKAs) show greatest promise: Raltegravir (Merck & Co) has been approved by the US Food and Drug Administration (FDA) for HIV-1 therapy, while elvitegravir (Gilead Sciences/ Japan (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=96 BACKGROUND: Two rotavirus vaccines are currently approved in the United States: 3-dose RotaTeq (RV5; Merck & Co., Inc., Whitehouse Station, NJ, USA) is administered at ages 2, 4, and 6 months; and 2-dose Rotarix (RV1; GlaxoSmithKline, Research Triangle Park, NC, USA) is administered at ages 2 and 4 months. Our objective was to compare rotavirus vaccine series completion and dosing schedule compliance between cohorts of infants who received these vaccines. METHODS: Infants aged less than 1 year (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=96 The synthesis and evaluation of small molecule antagonists of the G protein-coupled receptor NPBWR1 (GPR7) are reported for the first time. [4-(5-Chloropyridin-2-yl)piperazin-1-yl][(1S,2S,4R)-4-{[(1R)-1-(4-methoxyphenyl)ethyl]amino}-2-(thiophen-3-yl)cyclohexyl]methanone (1) emerged as a hit from a high-throughput screen. Examination of substituents that focused on replacing the 5-chloropyridine and 4-methoxybenzylamino groups of 1 led to the identification of compounds that exhibited (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=96 On October 25, 2011, the Advisory Committee on Immunization Practices (ACIP) recommended routine use of quadrivalent human papillomavirus (HPV) vaccine (HPV4; Gardasil, Merck & Co. Inc.) in males aged 11 or 12 years. ACIP also recommended vaccination with HPV4 for males aged 13 through 21 years who have not been vaccinated previously or who have not completed the 3-dose series; males aged 22 through 26 years may be vaccinated. These recommendations replace the October 2009 ACIP guidance that (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=96 NEW YORK-(BUSINESS WIRE)-Kent Klaudt of the national plaintiffs law firm Lieff Cabraser Heimann & Bernstein, LLP announced that Reba Inez Patton and her husband Patrick Patton of Tennessee have filed a lawsuit in the Superior Court of New Jersey against Merck & Co., the manufacturer of Fosamax, and GlaxoSmithKline, LLC, the manufacturer of Boniva, alleging these prescription drugs, which fall within the category of drugs known as bisphosphonates, increase the risk of atypical bone fractures (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=96 The evaluation of clinical proof of concept, optimal dose selection, and phase III probability of success has traditionally been conducted by a subjective and qualitative assessment of the efficacy and safety data. This, in part, was responsible for the numerous failed phase III programs in the past. The need to utilize more quantitative approaches to assess efficacy and safety profiles has never been greater. In this paper, we propose a framework that incorporates efficacy and safety data (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=96 : Covariate measurement error is common in epidemiologic studies. Current methods for correcting measurement error with information from external calibration samples are insufficient to provide valid adjusted inferences. We consider the problem of estimating the regression of an outcome Y on covariates X and Z, where Y and Z are observed, X is unobserved, but a variable W that measures X with error is observed. Information about measurement error is provided in an external calibration sample (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=96 The chief executive of Merck & Co (MRK.N) on Tuesday defended his refusal to slash the drugmaker's $8 billion research budget and warned that global price constraints threaten the pharmaceutical industry's ability to innovate. The drug industry is embroiled in a debate over whether companies are spending too much on research given a poor track record in developing new drugs. Investors are asking whether that money should be spent elsewhere to produce better financial returns. While Merck held (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=96 Background: Prior studies have found inverse associations between high-density lipoprotein cholesterol (HDL-C) or apolipoprotein A-I levels and cardiovascular disease (CVD). Whether this observation is consistent across low-density lipoprotein cholesterol (LDL-C) levels or total atherogenic particle burden (apolipoprotein B100) is less well-studied, particularly in women. Objective: To determine the association between HDL-C or apolipoprotein A-I level and CVD across a range of LDL-C and (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=96 ANN ARBOR, Mich.-(BUSINESS WIRE)-NanoBio Corporation today announced a preclinical collaboration with a subsidiary of Merck & Co., Inc., focused on the development of a vaccine for Respiratory Syncytial Virus (RSV). The studies will evaluate the combination of Merck s proprietary RSV antigen with NanoBio s NanoStat adjuvant technology for use as an intranasal vaccine. As part of the agreement, Merck has the option to negotiate a non-exclusive license to the NanoStat adjuvant for development (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=96 WHITEHOUSE STATION, N.J.-(BUSINESS WIRE)-Merck & Co., Inc., (NYSE:MRK), known as MSD outside the United States and Canada, today announced the establishment of an Asia Research & Development (R&D) headquarters for innovative drug discovery and development located in Beijing, China. The new facility is part of a $1.5 billion commitment the company has made to invest in R&D in China over the next five years. "The establishment of the MSD Asia R&D headquarters represents an important milestone (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=96 PALO ALTO, CA-(Marketwire - December 05, 2011) - TOPICA Pharmaceuticals, Inc., a privately held biotechnology company, today announced that Amir Tavakkol, Ph.D., has joined the company as senior vice president of clinical development and operations. With 20 years of experience in the pharmaceutical industry, consumer healthcare and academia, Dr. Tavakkol will be responsible for advancing the clinical development of luliconazole, TOPICA's broad-spectrum topical antifungal agent, for the (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=96 We have developed a novel series of pyrrolidine derived BACE-1 inhibitors. The potency of the weak initial lead structure was enhanced using library-based SAR methods. The series was then further advanced by rational design while maintaining a minimal ligand binding efficiency threshold. Ultimately, the co-crystal structure was obtained revealing that these inhibitors interacted with the enzyme in a unique fashion. In all, the potency of the series was enhanced by 4 orders of magnitude from (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=96 The methylotropic yeast Pichia pastoris has been used for more than two decades to successfully produce a large number of recombinant proteins. Currently, a wide variety of auxotrophic and drug based selection markers are employed to screen for clones expressing the protein of interest. For most proteins an increased copy number of the integrated plasmid results in higher levels of expression, but these multi-copy integrants can be unstable due to the propensity of P. pastoris for homologous (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=96 Objective:We assessed the immunogenicity and safety of a combination measles, mump, rubella, and varicella vaccine (MMRV) (ProQuad [Merck & Co, Inc, West Point, PA]) administered to healthy children concomitantly with a pneumococcal 7-valent conjugate vaccine (PCV-7) (Prevnar [Pfizer, Philadelphia, PA]).Patients and Methods:Healthy 12- to 15-month-old children who lacked vaccination and clinical histories for measles, mumps, rubella, varicella, and zoster but had written documentation of (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=96 Height is a model polygenic trait that is highly heritable. Genome-wide association studies have identified hundreds of single-nucleotide polymorphisms associated with stature, but the role of structural variation in determining height is largely unknown. We performed a genome-wide association study of copy-number variation and stature in a clinical cohort of children who had undergone comparative genomic hybridization (CGH) microarray analysis for clinical indications. We found that subjects (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=96 BACKGROUND: Findings of large randomised trials have shown that lowering LDL cholesterol with statins reduces vascular morbidity and mortality rapidly, but limited evidence exists about the long-term efficacy and safety of statin treatment. The aim of the extended follow-up of the Heart Protection Study (HPS) is to assess long-term efficacy and safety of lowering LDL cholesterol with statins, and here we report cause-specific mortality and major morbidity in the in-trial and post-trial (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=96 Context:Idiopathic infantile hypercalcemia (IIH) is a disorder the genetic etiology and physiological basis of which are not well understood.Objective:The objective of the study was to describe the underlying physiology and genetic cause of hypercalcemia in an infant with severe IIH and to extend these genetic findings into an additional cohort of children with IIH.Design:This was an inpatient study of a single patient with consanguineous parents at an academic medical center with follow-up in (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=96 Biomark Med. |-| Wagner JA. |-| Merck Research Laboratories, Merck & Co., Rahway, NJ 07065, USA. wagner@merck.com. text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=96 Raltegravir is a first-in-class HIV-1 integrase inhibitor with established antiviral efficacy in treatment-naive and treatment-experienced patients with multidrug-resistant HIV-1 infection. In this article, we summarize pharmacoeconomic evaluations of raltegravir-based treatment regimens, compared with alternative therapies, in the treatment of patients with HIV infection and/or AIDS. Cost-effectiveness evaluations of raltegravir in treatment-experienced patients conducted using a (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=96 Statin therapy is the mainstay of lipid-lowering therapy; however, many patients, particularly those at high risk, do not achieve sufficient LDL-cholesterol (LDL-C) lowering. Thus, there remains an unmet medical need for more effective and well tolerated lipid-lowering agents. Guidelines recommend combining additional lipid-lowering agents with a complementary mode of action for these patients. One approach to complementing statin therapy is combination with inhibitors that block the (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=96 Pichia pastoris is a methylotropic yeast that has gained great importance as an organism for protein expression in recent years. Here, we report the expression of recombinant human erythropoietin (rhEPO) in glycoengineered P. pastoris. We show that glycosylation fidelity is maintained in fermentation volumes spanning six orders of magnitude and that the protein can be purified to high homogeneity. In order to increase the half-life of rhEPO, the purified protein was coupled to polyethylene (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=96 Merck & Co. Inc. will pay $950 million to settle criminal and civil charges that it illegally promoted the painkiller Vioxx, the Justice Department announced Tuesday. The department said Merck will plead guilty to a misdemeanor offense and pay a $321.6 million criminal fine. The company is entering into a civil settlement in which it will pay $628 million to resolve additional allegations regarding off-label marketing of Vioxx and false statements about the drug's cardiovascular safety, the (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=96 TOULOUSE, France and ANN ARBOR, USA, 22 November 2011. Cerenis Therapeutics, a biopharmaceutical company developing novel high-density lipoprotein ( ˜HDL ) therapies for the treatment of cardiovascular and metabolic diseases, today announced the appointment of Dr. Richard C. Pasternak to the Board of Directors. Dr. Pasternak has had a long-standing research interest in lipid disorders and atherosclerosis, as well as prevention and patterns of practice and disease management. Previously, he (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=96 Mass spectrometry based proteomic experiments have advanced considerably over the past decade with high-resolution and mass accuracy tandem mass spectrometry (MS/MS) capabilities now allowing routine interrogation of large peptides and proteins. Often a major bottleneck to 'top-down' proteomics, however, is the ability to identify and characterize the complex peptides or proteins based on the acquired high-resolution MS/MS spectra. For biological samples containing proteins with multiple (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=96 FOSTER CITY, CA-(Marketwire - November 17, 2011) - SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that the Company will be added to the NASDAQ Biotechnology Index (NASDAQ: NBI). The semi-annual re-ranking of the index will become effective prior to market opening on Monday, November 21, 2011. "SciClone's inclusion in the NASDAQ Biotechnology Index underlines the solid progress the company is making and is another validation of our strategy of creating a market-leading, (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=96 Human onchocerciasis, a parasitic disease found in 28 African countries, six Latin American countries and Yemen, causes blindness and severe dermatological problems. In 1987, efforts to control this infection shifted from vector approaches to include the mass distribution of ivermectin - a drug donated by Merck & Co. for disease control in Africa and for disease elimination in the Americas. Currently, almost 25 years later, with the Americas being highly successful and now approaching (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=96 Obesity may be the greatest epidemic of modern times. It leads to diabetes and heart disease and shortens lifespan. Although not a risk factor for migraine, it is associated with an increased frequency and intensity of migraine. Obesity is also comorbid with chronic daily headache and is a major risk factor for chronification of episodic migraine in adults and children. Although obesity is not a factor in the effectiveness of migraine treatment, it does increase the peripheral and central (…)